Accueil   Diary - News   All news THERANEXUS, project accredited by Lyonbiopole, set to receive €6.2 million in funding

THERANEXUS, project accredited by Lyonbiopole, set to receive €6.2 million in funding

 

THERANEXUS, project accredited by Lyonbiopole, set to receive €6.2 million in funding from the French Investments for the Future program, managed by Bpifrance, for the development of Neurolead, its new lead generation platform targeting neuro-glia interactions

 

Lyon, 29 January 2019 – Theranexus (ALTHX) has been awarded a €6.2 million funding package through the Investments for the Future program (PIA), managed by Bpifrance (Structuring Research and Development Projects for Competitiveness, PSPC), supporting the development of the Neurolead program. Neurolead is coordinated by Theranexus, in collaboration with the Collège de France and the French Alternative Energies and Atomic Energy Commission (CEA), with the aim of designing and industrializing a unique drug candidate identification and characterization platform targeting interactions between the two major brain cell populations, neurons and glial cells, for treating neurological disorders

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree